PANBELA THERAPEUTICS INC (PBLA)

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Trial's lower-than-expected event rate suggests improved survival outcomes

Panbela Announces Poster Presentation at American Association for Cancer Research:

Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models 

Panbela Announces Transfer to OTCQB Market

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023

PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the fourth quarter...

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...

Panbela Therapeutics regains compliance with Nasdaq (NASDAQ:PBLA)

Panbela Therapeutics (PBLA) regains compliance with Nasdaq for bid price and publicly held shares, marking a positive development for the clinical stage...

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

Panbela Therapeutics closes ~$9M public offering of shares (NASDAQ:PBLA)

Biopharmaceutical company Panbela Therapeutics has closed ~$9M public offering of ~4.4M shares priced at $2.06 per share.

Panbela Announces Closing of Approximately $9.0 Million Public Offering

Panbela Announces Closing of Approximately $9.0 Million Public Offering

MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

Why Is Aclarion (ACON) Stock Down 16% Today?

Aclarion stock is falling on Monday after the company issued 500,000 shares of ACON to cover principal and accrued interest from notes.

Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?

Panbela Therapeutics stock is falling on Monday after pricing a public offering for PBLA shares well below its price closing price.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!

Panbela Therapeutics stock drops on stock offer (NASDAQ:PBLA)

Panbela Therapeutics (PBLA) stock lost ~62% in value after announcing a public offering to raise approximately $9.0M in gross proceeds. Read more here.

Panbela Announces Pricing of Approximately $9.0 Million Public Offering

Panbela Announces Pricing of Approximately $9.0 Million Public Offering

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!

Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Interim Data Analysis Anticipated in Mid-2024Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics,...